Outcomes following aortic valve replacement for isolated aortic stenosis with left ventricular dysfunction by Naicker, A et al.
290
Outcomes following aortic valve 
replacement for isolated aortic stenosis 
with left ventricular dysfunction
study was to determine the effects of AVR on left ventricular 
function and to describe the clinical outcomes in patients with 
isolated severe AS and LVD. The hypothesis was that AVR in 
patients with isolated AS and LVD improves LV function.
MATERIALS AND METHODS
Study population
Between 2004 and 2013, 1 573 chart records were analysed 
from the medical database of Inkosi Albert Luthuli Central 





Severe aortic stenosis (AS) is associated with a poor prognosis 
in patients with left ventricular dysfunction (LVD). Survival is 
estimated at less than 2 years in patients without aortic valve 
replacement (AVR).(1,2) A reduced ejection fraction may be 
related to the severity of the AS and chronic pressure overload 
of the left ventricle, rather than depressed myocardial con-
tractility (afterload mismatch). Relief of the valvular obstruction, 
by valve replacement, should allow recovery of left ventricular 
size and function.(3,4) However, there is a greater surgical risk 
and morbidity in patients with AS and LVD, which need to be 
considered.(5,6)
Most studies that have described the effects of AVR on ventri-
cular function included patients with coronary artery disease 
(CAD), which may contribute independently to LVD. Since the 
presence of CAD is associated with a reduced survival rate 
following AVR,(2) we aimed to eliminate this variable and 
evaluate the isolated effect of AVR in those without concomi-
tant CAD. There is no known published data available on 
survival, changes in ventricular function and long-term follow up 
from any South African institute to date. The purpose of this 
Background: Severe aortic stenosis (AS) is associated 
with a poor prognosis in patients with left ventricular 
dysfunction (LVD). Survival is estimated at less than 2 
years without aortic valve replacement (AVR). Limited 
data are available on the effects and outcomes of AVR in 
such patients, especially in the absence of concomitant 
coronary artery disease (CAD).
Methods:  This was a retrospective study which identifi ed 
33 patients over an approximate 10 year period who 
underwent surgical AVR for severe isolated AS and LVD 
(LVEF ≤50%). Patients were excluded if they had a prior 
valve replacement, mixed valve disease, <18 years old 
or the presence of CAD. Overall survival was analysed 
using the Kaplan-Meier curve and Cox proportional 
hazards model. The changes in postoperative LVEF and 
NYHA functional class, following AVR, was assessed 
using the Friedman test and ANOVA.
Results: Operative mortality was 15% with 5 deaths. 
Female sex and hyperlipidaemia were identifi ed as pre-
dictors of early mortality by univariate analysis. LVEF 
improved in survivors from a mean of 39 ± 10% - 49.8 ± 
8.7% at a 1 year follow-up (p=0.04). Younger age was 
identifi ed as an independent predictor of LVEF recovery 
(p=0.04). There was no difference in outcomes in 
patients with low baseline transvalvular gradients 
compared to those with higher gradients. There was 
signifi cant symptomatic improvement noted in all 
survivors following AVR (p<0.01).
Conclusion: Left ventricular function has a slower rate 
of recovery, compared to an earlier improvement of 
NYHA functional class after AVR for severe isolated 
AS and pre-operative LVD. In this high-risk group the 
fi ndings support AVR in patients with LVD. 
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records were used to identify patients who underwent surgical 
AVR for isolated AS in the presence of severe LVD defined as 
left ventricular ejection fraction (LVEF) ≤50%. Patients were 
excluded if they had undergone a prior valve replacement, 
mixed valve disease, <18 years old or the presence of CAD, as 
determined by cardiac catheterisation and coronary angiography. 
Thirty-three patients were eligible for entrance into the study 
and all medical records were reviewed retrospectively, includ-
ing clinical and demographic characteristics pre-operatively 
together with 2D Doppler echocardiographic results, operative 
and follow-up data. A EuroScore II model was calculated for 
each patient undergoing AVR to estimate the operative risk of 
mortality. The study was approved by the biomedical research 
committee of the University of KwaZulu-Natal.
Echocardiography
All patients underwent comprehensive 2D Doppler echo-
cardiographic examination performed by an experienced 
echocardiographer and all reports were assessed by a cardi-
ologist. The left ventricular diameters, ejection fraction, mean 
and peak aortic gradients, as well as the native valve orifice area 
were measured. LVEF was estimated by Teichholz M-mode 
method. No patients in the study group were noted to have 
undertaken stress echocardiography with dobutamine in the 
presence of low transvalvular gradients. 
Statistical analysis
Statistical analysis was performed using SPSS version 23 for 
Windows and Microsoft Excel. Continuous variables were 
expressed as mean ± standard deviation and as numbers with 
percentages for categorical variables. Continuous variables 
were compared with the 2 sample t test or Wilcoxon rank sum 
test when available, and categorical variables with the x2 test or 
Fisher exact test when available. For multivariate analysis, the 
factors associated with mortality on univariate analysis were 
entered into a model for logistic regression. Predictors of 
mortality with proven evidence demonstrated in the literature 
were also included into the model. Overall survival was analysed 
using the Kaplan-Meier and Cox proportional hazards model. 
The changes in the post-operative ejection fraction and New 
York Heart Association (NYHA) functional class following 
AVR was assessed using the Friedman test. A multivariate 
model of the analysis of variance (ANOVA) test and linear 
regression models was performed to assess the independent 
association between change in LVEF and patient variables. For 
all statistical tests, a p value of ≤0.05 was considered significant.
RESULTS
The pre-operative and demographic data are presented in 
Table I. The average age of patients was 65 ± 13.2 years (range 
44 - 89) with calcific AS being the common aetiology in the 
TABLE 1: Baseline characteristics of patients. 
Data are expressed as mean ± standard deviation (range) for 
continuous variables and n (%) for categorical variables. NYHA 
indicates New York Heart Association, ACE indicates angiotensin 
converting enzyme, LVEF indicates left ventricular ejection fraction.
Characteristic Findings (n=33)
Age, years 65 ±13
Gender (Male/Female) 18/15 (55/45)
Racial group
  African 10 (30)
  Indian 13 (40)
  White 9 (27)
  Coloured 1 (3)
Aetiology (n) %
  Calcifi c 29 (88)
  Congenital/bicuspid 3 (9)
  Rheumatic 1 (3)
Co-morbidities
  Hypertension 12 (36)
  Diabetes Mellitus 5 (15)
  Hyperlipidemai 3 (9)
  Nil 13 (39)
Syncope 10 (30)
NYHA Class
  Grade I 3 (9)
  Grade II 5 (15)
  Grade III 21 (64)
  Grade IV 4 (12)
Admission for heart failure 10 (30)
Rhythm
  Sinus 29 (88)
  Atrial fi brillation 4 (12)
Medical therapy
  Diuretics 27 (82)
  ACE inhibitor 11 (33)
  Calcium channel blocker 3 (9)
Smoker 7 (21)
Haemodynamic status
  Systolic arterial blood pressure, mmHg 122 ± 17
  Heart rate, beats per minute 98 ±17
LVEF, % 39 ± 10
Severity of LV dysfunction (LVEF %)
  Moderate (36 - 50%) 76 (25)
  Severe (21 - 35%) 15 (5)
  Very severe (<20%) 9 (3)
Aortic valve area, cm2 0.61 ± 0.26
Mean transvalvular gradient, mmHg 45.7 ± 18.6
Peak transvalvular gradient, mmHg 78.5 ± 29.1
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majority of patients (87.9%). Twenty-five patients (75.7%) were 
severely symptomatic (NYHA Class 3 and above) with 10 
patients (30.3%) requiring admission for heart failure. The 
average pre-operative ejection fraction was 39 ± 10% and 
mean valve area 0.61 ± 0.26cm2. 
Clinical outcome
Mortality
The 30 day hospital mortality was 15.1% (5 of 33 patients), in 
comparison to the EuroScore II predicted mortality risk of 
2.73% (Table II).  Three of the deaths occurred intra-operatively 
due to cardiac arrest and the other 2 as a result of complete 
heart block and intractable heart failure. The mean time to 
death, following admission, was 11 days ± 8. Female sex 
(p=0.01) and hyperlipidaemia (p=0.05) were identified as 
significant risk factors for death by univariate analysis (Table III). 
Other predictors which may be of clinical relevance included: 
older age (p=0.1), higher baseline heart rate (p=0.09), history 
of syncope (p=0.14) and prior admission for heart failure 
(p=0.14).
These factors, together with other familiar predictors of peri-
operative mortality found in the literature, were included in 
the multivariate logistic regression model. Older age (95% CI 
0.02 - 0.19, p=0.015), female sex (95% CI 0.03 - 0.65, p=0.029) 
and hyperlipidaemia (95% CI 0.14 - 1.09, p=0.013) were found 
to be independent predictors of peri-operative mortality.
All patients who died were in NYHA Class 3 pre-operatively 
but this was not significantly different to survivors. Those with 
low transvalvular gradients were not found to have an increased 
risk of mortality (Table IV).
Post-operative outcomes
The mean duration of stay in survivors was 17 days (±13). 
Twenty-one patients (75%) had no post-operative complica-
tions. Tachyarrhythmias, complete heart block requiring per-
manent pacing, deep vein thrombosis, worsening heart failure 
and acute kidney injury requiring renal replacement therapy 
were identified as the major causes of morbidity. 
Long-term survival and follow up
Figure 1 shows the Kaplan-Meir survival curve of the study 
population. Overall 1 year survival was predicted at 78.8% (95% 
CI: 0.61 - 0.89). Two patients were lost to follow-up and were 
not included in the survival analysis. No patients died during 
the follow-up period. The remaining survivors were followed 
up for a mean of 337 days ±150. There was a significant 
symptomatic improvement noted in all survivors following 
AVR (p<0.01). Seventy-five percent of patients were in NYHA 
Class 3 or 4 pre-operatively and none in the post-operative 
follow-up period (Table V). Three patients required readmission 
OUTCOMES FOLLOWING AVR
TABLE II: Observed and Predicted Operative Mortality 
Stratified by EuroSCORE II Risk Model.
Level of risk Number of Observed Predicted
 patients mortality % mortality %
  (actual number)
Low (0 - 2) 14 14.23 (2) 1.24
Moderate (2 - 5) 16 6.25 (1) 2.64
High (>5) 3 66.67 (2) 5.72
Overall 33 15.15 (5) 2.73
TABLE III: Univariate analysis of peri-operative mortality.
Data are expressed as mean ± standard deviation (range) for 
continuous variables and n (%) for categorical variables.  
Characteristic Survived Demised P value
 (n=28) (n=5)
Age, years 63 ± 12 74 ± 12 0.10
Gender (male/female) n (%) 18/10 (64/36) 0/5 (0/100) 0.01
Calcifi c AS 24 (86) 5 (100)  1.00
Hypertension 10 (36) 2 (40) 1.00
Diabetes Mellitus 3 (11) 2 (40) 0.15
Hyperlipidaemia 1 (4) 2 (40)  0.05
No known co-morbidities 13 (46) 0 (0) 0.13
Syncope 7 (25) 3 (60) 0.15
NYHA Class III - IV 20 (71) 5 (100) 0.34
Prior admission for heart failure 7 (25) 3 (60) 0.14
Atrial fi brillation 4 (14) 0 (0) 1.00
Smoker 5 (18) 2 (40) 0.30
Systolic blood pressure (mmHg) 123 ± 18 116 ± 7 0.44
Heart rate (beats/minute) 86 ± 18 98 ± 16 0.09
Type of prosthesis   0.49
  Mechanical 13 (46.4) 0 (0)
  Bioprosthesis 15 (53.6) 2 (40)
  Unknown due to intra- 0 (0) 3 (60)
  operative death
Prosthesis size (mm) 20.78 ± 2.51 21 ± 0 0.91
Baseline LVEF (%) 38.6 ± 11.2 42.8 ± 4.4 0.60
Aortic valve area (cm2) 0.61 ± 0.26 0.55 ± 0.24 0.71
Mean aortic valve 43.9 ± 17.6 55.6 ± 22.4 0.29
gradient (mmHg)
Peak aortic valve 75.9 ± 27.6 93 ± 36 0.37
gradient (mmHg)
Left atrial size (mm) 49.2 ± 10.8 47.8 ± 11.8 0.71













following AVR due to warfarin toxicity and heart failure. Cox 
proportional hazards model did not determine any significant 
factors that led to improved overall survival.
Echocardiographic changes
An analysis of variance (ANOVA) test concluded that a lower 
pre-operative LVEF was associated with prior admission for 
heart failure (p=0.01) and a smaller critical aortic valve area 
(p=0.03). An improvement of LVEF was noted in survivors 
from a mean of 39 ± 10% to 49.8 ± 8.7% at a mean 1 year 
follow-up period (p=0.04) (Figure 2). Further echocardio-
graphic analysis was analysed at a mean of 610 days ±123 days 
post aortic valve replacement, which further confirmed an 
improved LVEF of +9% in comparison to the pre-operative EF 
(p=0.02). Younger age (p=0.04) was the only identifiable 
significant independent predictor of LVEF recovery. By 
multivariate analysis, pre-operative to post-operative change 
in LVEF correlated with a sustained decline in the peak aortic 
valve gradient from a mean of 78.51 ± 29.11mmHg to 31.87 ± 
17.44 (p<0.01) at 1 year following AVR. Mean aortic valve 
gradients were not consistently recorded post-operatively and 
were therefore not analysed.
Patients with low mean transvalvular gradients (≤40mmHg) and 
those with high transvalvular gradients (>40mmHg) both 
demonstrated a similar improvement of LVEF recovery from 
baseline at 1 year following AVR (Table IV). 
 
TABLE V: Mean change in New York Heart Association 
(NYHA) Class between genders prior to and following 
aortic valve replacement.
Data are expressed as mean ± standard deviation. 
Gender  NYHA NYHA NYHA
 Class Class Class
 Pre-op at 3 months at 1 year
Male 2.55 ± 0.98 1.29 ± 0.59 1.25 ± 0.44
Female 3.06 ± 0.26 2.0 ± 0.87 1.62 ± 0.52
Total 2.78 ± 0.78 1.53 ± 0.76 1.36 ± 0.49
TABLE IV: Comparison of echocardiographic data and 
observed mortality of patients with high vs. low trans-
valvular gradients.
Echocardiographic data are expressed as mean ± standard deviation 
and mortality as n (%).




LVEF (%) 36.6 ± 12.3 41.2 ± 8.8 0.32
Aortic valve area (cm2) 0.65 ± 0.25 0.58 ± 0.27 0.42
Mean transvalvular  31.5 ± 11.0 56.1 ± 16.0 0.04
aortic gradient (mmHg)
Peak transvalvular  56.5 ± 15.6 94.6 ± 26.1 <0.01
aortic gradient (mmHg)
LVEF following AVR
  1 week 34.2 ± 10.7 36.5 ± 9.6 0.56
  6 months 36.1 ± 12.3 43.1 ± 13.7 0.22
  1 year 48.2 ± 9.1 51.4 ± 8.5 0.39
Peak gradient following  40.8 ± 17.7 23.6 ± 13.0 0.01
AVR at 1 year
Mortality 1 (7%) 4 (21%) 0.27
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FIGURE 2: Left ventricular ejection fractions (LVEF) depicted 
pre-operatively (pre-op) and during the follow-up period. Solid 
horizontal lines indicates mean EF; the rectangular box repre-
sents the upper and lower quartiles, and vertical line, the 

























In various studies and databases mortality rates in symptomatic 
and asymptomatic individuals undergoing AVR range from as 
low as 1 - 3% in patients younger than 70 years to as high as 
8% in older adults.(6)
In patients undergoing AVR for severe AS, LVD is a major 
prognostic indicator, with mortality rates of between 10 - 25% 
reported.(7,8) Despite increased mortality, AVR has been 
demonstrated to improve symptoms in survivors and improve 
survival compared to conservative management.(1,9) AVR is 
often not offered to these patients due to increased operative 
risk. Iung B, et al. found that 33% of patients in this group were 
declined AVR due to depressed LVEF (<50%) and advanced 
age.(10)
LVD may be due to concomitant coronary artery disease 
(CAD), a major cause of LVD,(11) and the mortality and 
outcomes of these patients may be influenced by dual 
pathology.
More recently, transcatheter aortic valve replacement (TAVR) 
has become a therapeutic recommendation in patients who 
have a high surgical risk.(12) However, when comparing TAVR 
to surgical AVR in patients with severe AS and LVD, no 
significant differences in mortality was found.(13,14) Currently, 
surgical AVR remains the gold standard in patients who are 
deemed fit for surgery. No patient in this study group under-
went TAVR due to unavailability of the procedure at the study 
centre.
The overall early mortality of 15% found in this study is similar 
to ranges previously reported.(15) All patients that demised 
were female with no evidence of a higher incidence of 
comorbidities. These findings are consistent with other sex-
based outcome studies following surgical AVR.(16,17) This, 
however, contrasted to the findings of a large New York study 
population of over 6 300 patients which found lower body 
surface area, which may or may not be linked to female sex, 
as a risk factor for medium term mortality following 
AVR.(18) Factors such as body fat composition, which may delay 
healing, as well as the postmenopausal state, which may confer 
an increased risk to death following surgery, have been 
postulated.(19) 
Although hyperlipidemia was identified as a statistically signi-
ficant risk factor for mortality (p=0.05), this should be a cautious 
interpretation considering the small sample size represented 
only 3 patients overall who had accompanying hyperlipidemia. 
Nevertheless, several studies have emerged that suggest AS 
is an active cellular process similar to atherosclerosis.(20,21) 
An elevated serum low density lipoprotein level has been 
proposed as a marker that increases the rate of disease 
progression in AS.(22,23)
Three of the 5 patients that demised had a history of syncope 
as well as a history of admission for heart failure. Although 
these characteristics did not approach statistical significance 
(p=0.14) it is certainly clinically relevant in this scenario. The 
average survival following the onset of syncope is estimated 
to be 2 - 3 years and in the presence of congestive cardiac 
failure at 1.5 years.(24) Therefore, prior to the development of 
symptoms and in the presence of concomitant LVD (LVEF 
<50%), AVR has been recommended as a Class I indication 
by the American College of Cardiology/American Heart 
Association guidelines and European Society of Cardiology 
guidelines.(6,12)
The cause of impaired left ventricular systolic function in 
patients with severe AS is multifactorial. Patients with impaired 
left ventricular systolic function not due to other causes, 
e.g. coronary artery disease, cardiomyopathy etc. have 2 basic 
causes namely afterload mismatch and contractile dysfunction. 
Afterload mismatch is characterised by the inability of myo-
cardial fibers to shorten due to severe obstruction at aortic 
valve level.(25) Wall stress is elevated in comparison to contractile 
dysfunction, but the measurement of wall stress is difficult and 
gradients across the aortic valve are used as a surrogate. Thus, 
patients with reduced ejection fraction with gradients in the 
severe range will have an improvement in ejection fraction 
when the obstruction is relieved.(3) 
In this study, no significant improvement was noted on LVEF on 
average at 1 week and 3 months post-operatively following 
AVR. This contrasted with findings of an earlier and sustained 
improvement in NYHA functional class at 3 months (p<0.01). 
At an approximate 1 year follow-up, however, a significant 
improvement in LVEF was evident (p=0.04). This data is similar 
to that reported by Robiolio et al. who examined 24 patients 
with severe AS (AVA <0.8cm). Fourteen of these patients 
had pre-operative LVD (LVEF <50%). It was noted that 
LVEF did not improve 1 week post-operatively, however, after 
6 months LVEF had significantly improved from a mean of 
38% to 57%.(26) Our study can therefore also conclude that 
left ventricular ejection fraction improves late after AVR in 
patients with AS and reduced ejection fraction. Considering the 
favourable response to surgery, it is also likely that afterload 
mismatch was the cause of the left ventricular dysfunction. The 
reason for a late recovery in LVEF may be inversely related to 
pre-operative LVD and the aortic valve area, as has been 
previously reported.(27) The most likely reason however, in the 
setting of this study, is probably related to the surgical 
intervention. Cardiac surgery results in several factors leading to 
myocardial stress that affect the post-operative course of 
patients. Triggers such as ischaemia, ischaemia-reperfusion, 
operative trauma and oxidative stress can lead to myocardial 
inflammation and apoptosis. This may eventually result in 
persistent myocardial dysfunction and prolonged depression of 













unavailable for reporting in this study, it has been identified as 
an independent predictor of post-operative LVD and severe 
cardiovascular morbidity, with an escalated risk of 1.4% per 1 
minute increase.(29)
Other factors associated with left ventricular recovery, following 
surgery, include the absence of a prior history of hypertension, 
heart failure and myocardial infarctions. Mild to moderate 
mismatch between patient body surface area and the prosthesis, 
including low post-operative aortic valve gradient, has also 
been shown to contribute to post-operative left ventricular 
dysfunction.(30)
LIMITATIONS
Due to the retrospective nature of the study, it was subject to 
selection bias and several limitations. This was a single centre 
study seeking to identify appropriate patients over a 10 year 
period. Given the rare association between isolated AS and 
LVD, which represents <5% of individuals with AS,(2) the 
relatively small sample size was expected. This limited the 
quality of results that could be produced and the ability to infer 
any significant conclusions from the risk factors associated 
with death. However, only a few larger series, with a maxi-
mum cohort of 46 such patients(15) were found in the literature, 
of which the outcomes were similar. Furthermore, Connolly, 
et al.(4) and Pereira, et al.(1) included patients with severe LVD 
and CAD below <35% , whereas in our study the baseline left 
ventricular function was only moderately impaired with an 
average of 39%. Post-operative mean aortic valve gradients 
were not documented in all patients and could thus not be 
analysed. This is due to the retrospective nature of the study 
and the lack of conformity between individual echo cardio-
grapher reporting. Ejection fraction was calculated from the 
Teicholtz method. This formula calculates LVEF from left 
ventricular linear dimensions, however, its reliability depends 
upon the geometric assumptions of the left ventricular shape. 
The accuracy of echocardiographic data could not be compared 
to the values obtained from complete cardiac catheterisation, 
as this invasive procedure was not performed in all patients. 
Regardless, Doppler echocardiography is considered reliable 
and is the preferred investigation to assess disease severity in 
AS.(6,31) Considering once again that all patients with co-morbid 
CAD and/or myocardial infarctions were excluded from our 
study it is unlikely that other variables, besides afterload mis-
match, may have had an influence on the LVEF which 
strengthens the validity of the results obtained. All our patients 
underwent surgical AVR; no patients were considered for 
transcatheter AVR due to the unavailability of the procedure. 
CONCLUSION
Left ventricular function has a slow rate of recovery, which 
improves late following AVR in patients with severe isolated 
AS and pre-operative LVD. Functional class improves early 
following valve replacement with a longstanding favourable 
clinical response. Unless a specific contraindication to surgery 
exists, the findings of this study support early AVR in patients 
with LVD, which is in line with previously published reports for 
this high risk group.
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